Other authors showed, in HER2+ metastatic BC patients, that a serum-based miRNA signature (miR451a, miR-16-5p, miR-17-3p and miR-940) can effectively distinguish patients who are sensitive to first-line trastuzumab plus chemotherapy from the resistant ones [100]. This evidence concerns the gene ERBB2 and breast cancer.